Management Insights for Optimizing Outcomes
in the Treatment of Hemophilia

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 20, 2018 to February 28, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bayer HealthCare Pharmaceuticals and Shire

Description:
Hemophilia is an inherited disorder caused by a defect in one of the X chromosomes resulting in excessive bleeding and easy bruising. Bleeding can be external or internal and bleeding into the joints is likely to cause long term damage if not treated quickly. In addition, bleeding in the brain is an even more serious problem for those with severe hemophilia as it can be caused by a simple head bump. While females are typically carriers of the genetic defect, the majority of cases are seen in males and it’s believed that 1 in 5,000 males are born with hemophilia every year. Hemophilia A is more common than B and each type require different treatments. Hemophilia is diagnosed through blood tests to determine the severity of the disease and discover which clotting factor is low or missing. Replacement therapy remains the mainstay of treatment which contain concentrates of clotting factor and is can be synthetic or made with human blood. Early treatment and prophylactic therapy is critical to effectively managing the disease and improving patient outcomes by preventing joint damage. Patient education is also critical as infusions can be taught to patients and done at home, alleviating unnecessary doctor appointments and lowering the cost of treatment. Demand therapy is less expensive however there is a risk that the delay in treatment can cause damage to joints and muscles. Another possibility for replacement therapy is having a vein access device implanted, which makes access easier. However, these devices can get infected and need proper care. Thankfully new and emerging treatments are becoming available and include longer lasting agents that cut down the number of infusions needed per year. These options have the potential to increase patient compliance while decreasing the possibility of inhibitors forming.

Upon Completion of this activity, participants will be able to:

  • Analyze clinical data and updated treatment guidelines evaluating current and emerging hemophilia prophylaxis therapies to ensure optimal management

  • Review the most recent clinical strategies for monitoring and managing inhibitors in patients with hemophilia

  • Identify the barriers of pharmacokinetic studies and coagulation assays in optimizing therapy for patients with hemophilia

  • Apply increased knowledge regarding the strategies, tools and scales to screen for, prevent, and manage comorbidities

  • Explore appropriate strategies for improving adherence among patients with hemophilia through education and collaboration between caregivers and healthcare providers
     

Faculty: Mark T. Reding, MD
Associate Professor of Medicine
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center

Disclosure:

Dr. Reding acts as an advisor or consultant for Bayer HealthCare, Bioverativ, Genentech, Novo Nordisk and Shire. He also serves as a speaker or a member of a speaker’s bureau for Bioverativ and Shire. He has received grants for clinical research from Bayer HealthCare. His presentation has been peer reviewed for any bias.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bayer HealthCare Pharmaceuticals and Shire

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue